KRYSTAL BIOTECH ($KRYS) posted quarterly earnings results for Q1 2026 on Monday, May 4th. The company reported earnings of $1.83 per share, beating estimates of $1.45 by $0.38. The company also reported revenue of $116,360,000, beating estimates of $114,374,895 by $1,985,105.
You can see Quiver Quantitative's $KRYS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KRYSTAL BIOTECH Insider Trading Activity
KRYSTAL BIOTECH insiders have traded $KRYS stock on the open market 84 times in the past 6 months. Of those trades, 0 have been purchases and 84 have been sales.
Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:
- DANIEL JANNEY has made 0 purchases and 22 sales selling 71,964 shares for an estimated $19,402,207.
- SUMA KRISHNAN (President, R&D) has made 0 purchases and 26 sales selling 75,000 shares for an estimated $17,587,603.
- KRISH S KRISHNAN (President and CEO) has made 0 purchases and 26 sales selling 75,000 shares for an estimated $17,586,611.
- DINO A ROSSI has made 0 purchases and 2 sales selling 18,950 shares for an estimated $4,953,694.
- KATHRYN ROMANO (Chief Accounting Officer) has made 0 purchases and 8 sales selling 13,250 shares for an estimated $3,602,405.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
KRYSTAL BIOTECH Hedge Fund Activity
We have seen 178 institutional investors add shares of KRYSTAL BIOTECH stock to their portfolio, and 144 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 776,739 shares (-95.9%) from their portfolio in Q4 2025, for an estimated $191,497,233
- BELLEVUE GROUP AG added 409,011 shares (+31174.6%) to their portfolio in Q4 2025, for an estimated $100,837,571
- BRAIDWELL LP removed 318,300 shares (-61.2%) from their portfolio in Q4 2025, for an estimated $78,473,682
- CITADEL ADVISORS LLC removed 250,483 shares (-39.3%) from their portfolio in Q4 2025, for an estimated $61,754,078
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 227,038 shares (+152.1%) to their portfolio in Q4 2025, for an estimated $55,973,948
- JANUS HENDERSON GROUP PLC added 209,369 shares (+2078.9%) to their portfolio in Q4 2025, for an estimated $51,617,833
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 200,000 shares (-29.1%) from their portfolio in Q4 2025, for an estimated $49,308,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
KRYSTAL BIOTECH Analyst Ratings
Wall Street analysts have issued reports on $KRYS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 01/22/2026
- Citigroup issued a "Buy" rating on 01/12/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
To track analyst ratings and price targets for KRYSTAL BIOTECH, check out Quiver Quantitative's $KRYS forecast page.
KRYSTAL BIOTECH Price Targets
Multiple analysts have issued price targets for $KRYS recently. We have seen 8 analysts offer price targets for $KRYS in the last 6 months, with a median target of $320.5.
Here are some recent targets:
- Debjit Chattopadhyay from Guggenheim set a target price of $284.0 on 02/25/2026
- Geulah Livshits from Chardan Capital set a target price of $323.0 on 02/18/2026
- Yigal Nochomovitz from Citigroup set a target price of $371.0 on 02/18/2026
- Roger Song from Jefferies set a target price of $371.0 on 02/17/2026
- Andrea Tan from Goldman Sachs set a target price of $327.0 on 02/02/2026
- Alec Stranahan from B of A Securities set a target price of $318.0 on 01/22/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $310.0 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
